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The Survival and Ventricular Enlargement (SAVE) trial and 
other similar studies have clearly demonstrated that clinical 
benefits can be derived by prescribing angiotension- 
converting enzyme inhibitors for patients with substantial 
left ventricular dysfunction after a myocardial infarction. 
For example, risk reductions from 21% to 17% for death, 
17% to 14% for hospital admission for heart failure and 
15% to 12% for recurrent myocardial infarction were attrib- 
uted to captopril during an average follow-up period of 42 
months in the SAVE trial (1). Undoubtedly, the cost of 
angiotensin-converting enzyme therapy is justified for those 
who experience these types of benefits. In a world with 
unlimited resources for health care, all treatments hat have 
demonstrated fficacy would be utilized to benefit as many 
people as possible. However, when resources of the payer 
are limited, someone must decide how to allocate resources 
to derive the greatest benefit for a group of patients. Are 
physicians willing to change their long-standing approach to 
managing patients from being an advocate for each individ- 
ual patient regardless of cost to one of allocating resources 
among a group of patients? If not, government or health 
care administrators may become even more involved in 
clinical practice through incentives or restrictions designed 
to foster the use of the most cost-effective medical interven- 
tions. 
Given limited resources, use of medical interventions 
based on incremental cost effectiveness will provide more 
benefit than any other method of allocating resources, 
assuming that benefits accruing to all patients in a health 
care system are valued equally (2,3). For example, a cost- 
effectiveness analysis might estimate that medications A and 
B provide 10 and 4 "benefit units" and incur costs~f $5,000 
and $500, respectively. If one had $25,000 to spend, one 
could get 50 benefit units by treating 5 patients with 
medication A or 200 benefit units by treating 50 patients 
with medication B. Note that even though medication A
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offers greater benefit to an i dividual than medication B, its 
cost is such that use of medication B provides more total 
benefit for the available resources. Therefore, even though 
angiotensin-converting e zyme inhibitors have been shown 
to be effective in selected patients who have experienced a 
myocardial infarction, one might ask whether the cost of 
gaining these benefits is favorable compared with use of the 
same health care dollars for other medical interventions; for 
example, the use of hydroxymethylglutaryl coenzyme A 
reductase inhibitors after a myocardial infarction (4). 
The primary measure for comparing treatments i  the 
incremental cost-effectiveness ratio, which is commonly 
calculated to represent he cost of gaining one quality- 
adjusted life-year compared with some alternative treatment 
or no treatment. At this time, there appear to be substantial 
methodologic differences in how benefits and costs are 
estimated in different studies, thereby making it difficult to 
compare cost-effectiveness ratios (5). Furthermore, one 
must ascertain whether or not the stimates of costs, utilities 
and survival can be extrapolated. Sensitivity analysis can 
help determine how different estimates affect he incremen- 
tal cost-effectiveness ratio, although the number of permu- 
tations in these complex models can be overwhelming. 
Given these caveats, are you and your patients willing to 
accept treatment decisions based on current methods of 
cost-effectiveness analysis? Those who are knowingly denied 
medical services may question their validity. In addition, an 
individual patient's values may differ from those used to 
calculate cost effectiveness (6).Therefore, clinicians need to 
understand cost-effectiveness analysis to help patients com- 
prehend health care policies and perhaps challenge admin- 
istrative decisions that directly affect patient care. 
In this issue of the Journal, Tsevat et al. (7) provide a 
cost-effectiveness analysis of captopril compared with no 
angiotensin-converting e zyme inhibitor on the basis of 
estimates from the SAVE trial and local substudies. The 
cost per quality adjusted life-year gained appears to be far 
from the least favorable xpenditure of medical care, al- 
though currently available analyses are insufficient to pre- 
cisely rank the cost-effectiveness of angiotensin-converting 
enzyme inhibitors after myocardial infarction among many 
other potential uses of health care resources. As with all 
analysis, there was some imprecision in the estimates used 
to calculate cost-effectiveness. The analysis was subgrouped 
by age even though there was no statistically significant 
interaction between age and the treatment effect in the 
SAVE trial (1). Survival estimates were actually worse with 
captopril in the 50- to 59-year old subgroup, but the 
variation in treatment effect with age was smoothed by 
regression analysis. Can one be confident hat the differ- 
ences in treatment effects between the various age groups 
were not due to sampling variation? In addition, the sample 
used to estimate utilities was too small to firmly establish 
whether utilities varied by age. It is not clear whether the 
sensitivity analyses covered the entire width of the 95% 
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confidence intervals for the estimated probabilities of 
survival and utilities. Therefore, a degree of doubt exist 
about he cost-effectiveness ratios for this treatment, partic- 
ularly for a large 50- to 59-year old subgroup where the 
incremental cost effectiveness was sensitive to the estimates 
used. 
Hopefully, cost-effectiveness analyses will help practioners 
make more judicious use of available health care resources. 
Such analyses should not dictate the standard of care but can 
help to inform the decision. Societal input will be necessary in
the larger context of choosing how to utilize limited resources. 
Studies uch as that by Tseval et al. in this issue of the Journal 
should prove helpful in this regard as economic analyses 
become an increasingly common component of clinical trials 
and clinical practice. 
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